|Ridaforolimus (Code C49061)|
|Terms & Properties|
Preferred Name: Ridaforolimus
Definition: A small molecule and non-prodrug analogue of the lipophilic macrolide antibiotic rapamycin with potential antitumor activity. Ridaforolimus binds to and inhibits the mammalian target of rapamycin (mTOR), which may result in cell cycle arrest and, consequently, the inhibition of tumor cell growth and proliferation. Upregulated in some tumors, mTOR is a serine/threonine kinase involved in regulating cellular proliferation, motility, and survival that is located downstream of the PI3K/Akt signaling pathway.
NCI-GLOSS Definition: A substance being studied in the treatment of soft tissue and bone cancers. It is also being studied in the treatment of other solid tumors and hematologic cancer. Ridaforolimus stops cells from dividing and may cause cancer cells to die. It is a type of mTOR inhibitor.
Display Name: Ridaforolimus
NCI Metathesaurus Link: C2713007 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
External Source Codes:
|CAS Registry Number||572924-54-0 (see NLM ChemIDplus info)|
|FDA UNII Code||48Z35KB15K|
|PDQ Closed Trial Search ID||354223|
|PDQ Open Trial Search ID||354223 (check for NCI PDQ open clinical trial info)|
|Name||Value (qualifiers indented underneath)|
Additional Concept Data:
|Defined Fully by Roles: No|